HRMYHarmony Biosciences Holdings, Inc.

HRMY Stock Price, Valuation & Chart | Harmony Biosciences Holdings, Inc.

Compare

$42.860+1.61 (+3.90%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology HRMY intrinsic value HRMY calculated fair value vs price

Overview Financials Dividends Ratios

HRMY Historical price chart

HRMY Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization2.48B

PE Ratio13.92

EPS3.08

Trading Volume1.11M

Today's High/Low43.02/41.25

Dividend Yield0.00

52 Week High/Low43.02/25.52

Shares Outstanding57.89M

HRMY Financial Statement

HRMY Analyst ratings

HRMY Analysis & performance metrics

HRMY Company profile

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the…

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name…

HRMY Management team

Name

Position

Cate McCanless

Senior Vice President & Chief Corporate Affairs Officer

Brennan Doyle

Vice President & Head of Investor Relations

Christian Ulrich J.D.

General Counsel & Corporate Secretary

Sandip S. Kapadia CPA, M.B.A.CFO

Executive Vice President, Chief Administrative Officer & Chief Financial Officer

Andrew Serafin J.D., M.B.A.

Executive Vice President & Chief Strategy Officer

Audrey Murphy SPHR

Chief Human Resources Officer

Kumar Budur M.D., M.S.

Executive Vice President and Chief Medical & Scientific Officer

Tricia Glover

Chief Compliance Officer

Name

Position

Cate McCanless

Senior Vice President & Chief Corporate Affairs Officer

Brennan Doyle

Vice President & Head of Investor Relations

Christian Ulrich J.D.

General Counsel & Corporate Secretary

Sandip S. Kapadia CPA, M.B.A.CFO

Executive Vice President, Chief Administrative Officer & Chief Financial Officer

Andrew Serafin J.D., M.B.A.

Executive Vice President & Chief Strategy Officer

Audrey Murphy SPHR

Chief Human Resources Officer

Kumar Budur M.D., M.S.

Executive Vice President and Chief Medical & Scientific Officer

Tricia Glover

Chief Compliance Officer

Management Team

Cate McCanless

Senior Vice President & Chief Corporate Affairs Officer

Brennan Doyle

Vice President & Head of Investor Relations

Christian Ulrich J.D.

General Counsel & Corporate Secretary

Sandip S. Kapadia CPA, M.B.A.CFO

Executive Vice President, Chief Administrative Officer & Chief Financial Officer

Andrew Serafin J.D., M.B.A.

Executive Vice President & Chief Strategy Officer

Audrey Murphy SPHR

Chief Human Resources Officer

Kumar Budur M.D., M.S.

Executive Vice President and Chief Medical & Scientific Officer

Tricia Glover

Chief Compliance Officer

Management

Cate McCanless

Senior Vice President & Chief Corporate Affairs Officer

Brennan Doyle

Vice President & Head of Investor Relations

Christian Ulrich J.D.

General Counsel & Corporate Secretary

Sandip S. Kapadia CPA, M.B.A.CFO

Executive Vice President, Chief Administrative Officer & Chief Financial Officer

Andrew Serafin J.D., M.B.A.

Executive Vice President & Chief Strategy Officer

Audrey Murphy SPHR

Chief Human Resources Officer

Kumar Budur M.D., M.S.

Executive Vice President and Chief Medical & Scientific Officer

Tricia Glover

Chief Compliance Officer

Total 8 executives

HRMY Frequently asked questions

What is Harmony Biosciences Holdings, Inc. (HRMY) Stock Price?

Current stock price of Harmony Biosciences Holdings, Inc. (HRMY) stock is $42.860. The stock price is +3.90% higher in the session. The intraday range can be seen from this page. Volume of Harmony Biosciences Holdings, Inc. (HRMY) stock is 1.11M.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Harmony Biosciences Holdings, Inc. (HRMY) stock price going up or down today?

The stock price of Harmony Biosciences Holdings, Inc. (HRMY) can change with earnings, company news, and overall market sentiment. Harmony Biosciences Holdings, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Harmony Biosciences Holdings, Inc. stock expensive at its current price?

Whether Harmony Biosciences Holdings, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for HRMY on this page is 13.92. EPS on this page is 3.08. Compare those figures with peers and growth expectations before deciding if the current Harmony Biosciences Holdings, Inc. price is justified.

How has the stock price of Harmony Biosciences Holdings, Inc. (HRMY) performed historically?

Historical performance for Harmony Biosciences Holdings, Inc. (HRMY) is shown on the price chart on this page. Review multi-period moves alongside volume to see how HRMY reacted to past earnings and market events.

Should I buy Harmony Biosciences Holdings, Inc. (HRMY) stock, at this price?

Buying Harmony Biosciences Holdings, Inc. (HRMY) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.